

SÚČASNÝ STAV V CHIRURGICKEJ LIEČBE KAROTÍD V NÚSCH



TOMKA J., DULKA T., GAŽI A.


Klinika cievnej chirurgie, NÚSCH, a.s.

XXII. SLOVENSKÝ KONGRES CIEVNEJ CHIRURGIE

5. - 7. 4. 2018, JASNÁ



■ De Bakey, august 1953 -CEA



■ Mathias 1989 – CAS



■ Edward B. Diethrich (USA) - CAS

Karotické endarterektómie 2010-2016 v SR



Editor's Choice – Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)

Writing Group ^a, A.R. Naylor, J.-B. Ricco, G.J. de Borst, S. Debus, J. de Haro, A. Halliday, G. Hamilton, J. Kakisis, S. Kakkos, S. Lepidi, H.S. Markus, D.J. McCabe, J. Roy, H. Sillesen, J.C. van den Berg, F. Vermassen, ESVS Guidelines Committee ^b, P. Kolh, N. Chakfe, R.J. Hinchliffe, I. Koncar, J.S. Lindholt, M. Vega de Ceniga, F. Verzini, ESVS Guideline Reviewers ^c, J. Archie, S. Bellmunt, A. Chaudhuri, M. Koelemay, A.-K. Lindahl, F. Padberg, M. Venermo

Keywords: Carotid, Vertebral, Stroke, Transient ischaemic attack, Endarterectomy, Stenting, Medical therapy, Screening, Dementia, Asymptomatic, Symptomatic, Thrombolysis, Imaging, Bypass, Surgical techniques, Complications, Patch infection, Restenosis

TABLE OF CONTENTS

What have the 2017 guidelines added to the 2009 Guidelines?	7
1. Methodology and Grading of Recommendations	8
1.1. Purpose of the guidelines	8
1.2. The Writing Group	8
1.3. Evidence collection	8
1.4. Recommendations	8
1.5. The review process and update of guidelines	8
1.6. Definition of primary, secondary, and tertiary prevention	8
2. Management of Carotid Artery Disease	9
2.1. Introduction	9
2.1.1. Burden of stroke	9
2.1.2. Definition of stroke and transient ischaemic attack	9
2.1.3. Aetiology of carotid territory ischaemic stroke	9
2.1.4. Methods for measuring carotid artery stenosis severity	9
2.1.5. Imaging strategies in carotid artery disease	10
2.1.6. Role of the multidisciplinary team	10
2.2. Secondary prevention in asymptomatic patients	11
2.2.1. Optimal medical therapy	11
2.2.1.1. Risk factor control	11
2.2.1.2. Antiplatelet therapy	11
2.2.1.3. Lipid-lowering therapy	12
2.2.1.4. Management of hypertension	12
2.2.1.5. Treatment in diabetic patients	13
2.2.1.6. Adherence to optimal medical therapy	13
2.2.2. Screening for asymptomatic carotid stenoses	13
2.2.2.1. Is stroke important to prevent?	13
2.2.2.2. Is Duplex ultrasound reliable for diagnosing stenosis severity?	13
2.2.2.3. Prevalence of asymptomatic carotid disease	14
2.2.2.4. Can a "high risk for stenosis" cohort be identified?	14
2.2.2.5. Potential benefits of selective screening	14
2.2.2.6. Harm associated with screening	14
2.2.2.7. Harm associated with carotid interventions	14
2.2.2.8. Does screening prevent fatal or nonfatal ipsilateral stroke?	14
2.2.2.9. Who advocates population or selective screening?	14
2.2.2.10. Interventions in asymptomatic patients	15
2.2.3.1. Randomised trials: endarterectomy versus best medical therapy	15

For full list of Author's affiliations, please refer to Appendix.

^a **Writing Group:** A.R. Naylor (Leicester, UK, co-chairman),* J.-B. Ricco (Strasbourg, France, co-chairman), G.J. de Borst (Utrecht, Netherlands), S. Debus (Hamburg, Germany), J. de Haro (Madrid, Spain), A. Halliday (Oxford, UK), G. Hamilton (London, UK), J. Kakisis (Athens, Greece), S. Kakkos (Patras, Greece), S. Lepidi (Padova, Italy), H.S. Markus (Cambridge, UK), D.J. McCabe (Dublin, Ireland), J. Roy (Stockholm, Sweden), H. Sillesen (Copenhagen, Denmark), J.C. van den Berg (Lugano/Bern, Switzerland), F. Vermassen (Ghent, Belgium).


^b **ESVS Guidelines Committee:** P. Kolh (Liege, Belgium), N. Chakfe (Strasbourg, France), R.J. Hinchliffe (Bristol, UK), I. Koncar (Belgrade, Serbia), J.S. Lindholt (Odense, Denmark), M. Vega de Ceniga (Galdakao, Spain), F. Verzini (Perugia, Italy).

^c **ESVS Guideline Reviewers:** M. Vega de Ceniga (Review Coordinator) (Galdakao, Spain), J. Archie (Raleigh, USA), S. Bellmunt (Barcelona, Spain), A. Chaudhuri (Bedford, UK), M. Koelemay (Amsterdam, Netherlands), A.-K. Lindahl (Oslo, Norway), F. Padberg (Newark, USA), M. Venermo (Helsinki, Finland).

* Corresponding author. E-mail address: ross.naylor@uhl-tr.nhs.uk

1078-5884/© 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

<http://dx.doi.org/10.1016/j.ejvs.2017.06.021>



European Journal of Vascular & Endovascular Surgery

www.ejvs.com

ISSUE HIGHLIGHTS

Editor's Choice – ESVS Carotid and Vertebral Artery Disease Guidelines

Editor's Choice – Calcification of Aortic Aneurysms and Mortality/Morbidity

Psoas Muscle Area in Patients with Asymptomatic AAA

Endovascular Repair of Acute Thoracoabdominal Aortic Aneurysms


Outcomes of Patients with CLI in the EUCLID Trial

Graduate Elastic Compression Stockings In Patients with Symptomatic Varicose Veins

Chirurgia karotíd (2014-2016)

NÚSCH, a.s.

750 pacientov
458 mužov
292 žien




OPERAČNÉ VÝKONY

❑ Everzné CEA	497 (66%)
❑ Štandardné CEA	138 (18%)
❑ Kinking ACI	98 (13%)
❑ Iné výkony	17 (1%)
❑ Bez intraluminálneho shuntu	(98%)
❑ V cervikálnom bloku	(95%)

OPERAČNÉ VÝKONY


■	Asymptomatické pacienti	456	(71,4%)
■	Symptomatické pacienti	183	(28,6%)




KOMPLIKÁCIE



Periproceduálne LIM 8 (1,07%)

Revízie pre krvácanie (hematóm) 18 (2,4%)




CEA







Everzná endarterektómia



Everzná endarterektómia

KINKING ACI




Neurologická symptomatológia a stupeň stenózy

- Absolútna indikácia CAD > 70% [A]
 - CMM < 6%
- CEA je kontraindikovaná pri symptomatických pacientoch < 50% [A]
- CEA má byť realizovaná do 14 dní od TIA [A]
- CEA sa odporúča v pásme 70-99% asymptomatickej stenózy ak riziko CMM < 3%

Local Anesthesia

Perioperative Brain Protection



- All patients showing neurological deficit after carotid cross-clamping awake testing are shunted afterwards

General Anesthesia – Perioperative Brain Protection



TCO (Transcranial Cerebral Oximetry) shows carotid clamping decline in **rSO²** (regional brain oxygen saturation) ➡ **more than 20 %** below the baseline level ➡ indication of **critical cerebral ischemia** ➡ **carotid intraluminal shunt**

Konzervatívna liečba



➤ **Antiagregačná liečba**

- Aspirín sa nemusí vysadiť
- Clopidogrel - nie je definitívne rozhodnuté či je ho nutné vysadiť peroperačne

➤ **Antikoagulačná liečba** sa má vysadiť 5-6 dní pred operáciou a nahradiť LMWH alebo nefrakciovaným heparínom

➤ Statíny sa nevysadzujú

Aspirín a statíny sú indikované pred, počas a po CEA [A]



Explantácia stentu z karotického riečiska po CAS

Záver

Operácie karotíd sú v rukách skúsených vaskulárnych chirurgov bezpečným výkonom s evidentným benefitom pre pacienta v zmysle primárnej a sekundárnej prevencie NCMP.

